comparemela.com

Latest Breaking News On - Adverse outcomes - Page 5 : comparemela.com

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

Men and women respond similarly and positively to heart failure treatment with dapagliflozin

When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.

New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease

Dapagliflozin is cost-effective for chronic kidney disease compared with standard of care, in the UK, Germany, and Spain, despite the fact that the drug has high acquisition costs, finds a new analysis.

Dapagliflozin May Be Cost-Effective for Treating CKD

FRIDAY, Nov. 4, 2022 (HealthDay News) Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, according to a study published online Nov. 2 in the Clinical Journal of the American Society

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.